Article
Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.
Pigment cell & melanoma research - 1 Nov 2014
Rebecca Vito W, Alicea Gretchen M, Paraiso Kim H T, Lawrence Harshani, Gibney Geoffrey T, Smalley Keiran S M
Abstract excerpt
The MEK inhibitor MEK162 is the first targeted therapy agent with clinical activity in patients whose melanomas harbor NRAS mutations; however, median PFS is 3.7 months, suggesting the rapid onset of resistance in the majority of patients. Here, we show that treatment of NRAS-mutant melanoma cell lines with the MEK inhibitors AZD6244 or trametinib resulted in a rebound activation of phospho-ERK (pERK)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.